$PRME News
Last published 21h ago
- 21h agoPRMEPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 41,071,428 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,357,142 additio ...
- 21h agoPRMEPrime Medicine, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02
- 21h agoPRMEPrime Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 --
- 2d agoPRMEPrime Medicine Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share. Prime Medicine has also granted the underwrit ...
- 2d agoPRMEPrime Medicine, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 2d agoPRMEPrime Medicine Announces Proposed $125.0 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purc ...
- 4d agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 1mo agoPRMEMorgan Stanley 24th Annual Global Healthcare Conference - PRIME MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everyone. My name is Chris Yu. I'm on Terrence Flynn's team covering biopharma and biotech companies. I am delighted to host Alan Ryan, CEO of Prime Medicine. Before we start, for important discl
- 1mo agoPRMEPrime Medicine - 1773617 - PRIME MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everyone. My name is Chris Yu. I'm on Terrence Flynn's team covering biopharma and biotech companies. I am delighted to host Alan Ryan, CEO of Prime Medicine. Before we start, for important discl
- 2mo agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 3mo agoPRMEPrime Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable
- 3mo agoPRMEPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson DiseaseGlobeNewswire-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent
- 4mo agoPRMEPrime Medicine Announces Positive Resolution to Arbitration with Beam TherapeuticsGlobeNewswire-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to
- 4mo agoPRMEPrime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)GlobeNewswire-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47phox-deficient CGD
- 4mo agoPRMEPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson DiseaseGlobeNewswire-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --
- 5mo agoPRMEPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 5mo agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 6mo agoPRMEPrime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward
- 7mo agoPRMEPrime Medicine Appoints Svetlana Makhni as Chief Financial OfficerGlobeNewswireCAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 7mo agoPRMEMDGLIOVADNLIThe $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepPR NewswireThe FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell...
- 7mo agoPRMEMDGLIOVADNLIAdvanced Cell-based Therapy Booming the Success for Healthcare SectorPR NewswireUSANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578...
- 8mo agoPRMEPrime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to
- 8mo agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 10mo agoPRMEPrime Medicine to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 10mo agoVRTXCRSPPRMEMDGLGene Therapy: 5 Biotech Stocks Chasing the $36B PrizePR NewswireEquity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments...
- 11mo agoPRMEPrime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseGlobeNewswireCAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 11mo agoPRMEPrime Medicine to Present at 8th Annual Evercore Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMECORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development
- 1y agoPRMEPrime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate
- 1y agoPRMEPrime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business OfficerGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease StrategyGlobeNewswireCAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoPRMEPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on
- 1y agoPRMEPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Pricing of Public OfferingGlobeNewswireCAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisGlobeNewswire-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis
- 1y agoPRMEPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced
- 1y agoPRMEPrime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership TransitionGlobeNewswire-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's
- 1y agoPRMEPrime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous DiseaseGlobeNewswire-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66%
- 1y agoPRMEPrime Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND
- 1y agoPRMEPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewswire-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing
- 1y agoPRMEPrime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswire-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 --
- 1y agoPRMEPrime Medicine to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today
- 1y agoPRMEKuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME)...
- 1y agoPRMEPrime Medicine to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced